Dalotuzumab

• CAT Number: I042254
• CAS Number: 1005389-60-5
• Molecular Weight: 146.4 (kDa)
• Purity: ≥95%

Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo[1][2][3].
Dalotuzumab (h7C10; 33 nM; 24 h) inhibits IGF-1- and IGF-2-induced proliferation of MCF7 estrogen-dependent breast cancer cells with IC50 values of 4.2 and 3.1 nM, respectively[1].
Dalotuzumab (33 nM; 24 h) induces cycle arrest and inhibits autophosphorylation of the IGF-IR and IRS-1, in MCF7 cells (IGF-1-induced)[1].
Dalotuzumab increases NK cell-mediated lysis of MCF7 and A459 cells by 26 and 25%, respectively[1].
Dalotuzumab (MK-0646; 10 µg/mL; 24, 48 h) abrogates the anti-apoptotic effect of IGF1 in endometrial cancer cells[2].
Dalotuzumab (h7C10; i.p.; 250 µg/mice for the first time, then 125 µg/mice twice weekly for 40 days) shows anti-tumor effects on MCF-7 and A549 xenograft tumor models[1].

Reference

[1]. Goetsch L, et al. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer. 2005 Jan 10;113(2):316-28.
 [Content Brief]

[2]. Bitelman C, et al. IGF1R-directed targeted therapy enhances the cytotoxic effect of chemotherapy in endometrial cancer. Cancer Lett. 2013 Jul 10;335(1):153-9.
 [Content Brief]

[3]. Scartozzi M, et al. Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. Curr Opin Mol Ther. 2010 Jun;12(3):361-71.
 [Content Brief]